Dr. Lal PathLabs launches India’s first dedicated Complement Testing Laboratory

26 Nov 2025 Evaluate

Dr. Lal PathLabs (DLPL) has launched India’s first dedicated Complement Testing Laboratory, strengthening its position as India’s leading hub for autoimmune diagnostics. This advanced facility brings globally benchmarked complement assays to Indian patients, several for the first time in the country, helping doctors diagnose autoimmune, kidney, and recurrent infection related conditions faster, more accurately, and at earlier stages.

The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards. For patients living with autoimmune or inflammatory conditions, the launch offers greater clarity and control over disease management. Early and precise diagnosis means better treatment outcomes, reduced healthcare costs, and improved quality of life.

Dr. Lal Pathlabs is a provider of diagnostic and related healthcare tests and services in India.


Dr. Lal Pathlabs Share Price

3025.95 -28.50 (-0.93%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Apollo Hospital Ent. 7189.25
Max Healthcare Inst 1097.95
Narayana Hrudayalay 1916.45
Aster DM Healthcare 635.10
Global Health 1163.75
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×